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1058-95 Reproducibility of High Resolution Magnetic Resonance 
Imaging for In Vivo Monitoring of Atherosclerotic 
Lesions in Humans 
Roberto Corti, Zahi A. Fayad, Valentin Fuster, Frank Macaluso, Juan J. Badimon, 
Cardiovascular Biology Research Laboratory. Cardiovascular/nstitute.Mount Sinai 
School of Medicine, New York, New York. 
Background: MRI allows the in-viva sequential monitoring of human atherosclorotic 
lesions. The purpose of this study was to investigate the reproducibility of non-invasive 
MRI for in viva quantification of human atherosclerotic lesions. 
Method: Two consecutive independent scans of the thoracic aorta and carotid arteries 
were performed in 9 asymptomatic hypercholesterolemic patients. MRI was performed 
using high-resolution black-blood technique. Special attention was given to match MRI of 
the aortic (n=9) and carotid (n=7) plaques using several anatomical landmarks. Lumen 
area (LA), total vascular area (TVA) and vessel wall area (VWA=TVA-LA) were calcu- 
lated by computer-assisted tracing of cross-sectional vessel images. The image specific 
error (ISE) was defined as the absolute difference in the tracing of matched images. Per- 
centage error = (ISE/mean of 2 tracings)*100%. 
Results: Aortic Lesions: The mean LA was 462±143mm2 with a VWA of 245±66 mm2. 
The absolute ISE when measuring VWA was 11±8 ram2; however when the average 
measurement of 5 sections were considered, the error was markedly reduced to a 6±4 
ram2 corresponding to an error of 2.4±1.7%. 
Carotid Lesion: The mean I_A was 34±10mm2 with a VWA of 48±18 ram2. The absolute 
ISE when measuring VWA was 3±3 ram2; however when the average measurement of 5 
sections were considered, the error was markedly reduced to a 1±1 ram2 corresponding 
to an error of 3.0±2.5%. 
Based on the reported data on reproducibility changes in plaque size of more than 5% for 
aortic and 7% for carotids (corresponding to 2*SD) considering the average of 5 contigu- 
ous images for comparison, will be "real" and accurately detected by MRI. 
Conclusions: High-resolution MRI allows the precise and reproducible assessment of 
human atheroscleretic lesions in viva which is needed for monitoring sequential changes 
in plaque size and to study the effectiveness of different treatments (vg. lipid-lowering) in 
follow-up studies. 
1058-96 Atheroeclerotic Plaques, Inflammation, and Thoracic 
Aortic Dilatation: Insights From a Population-Based 
Transesophageal Echocardiographic Study With 
Implications for Aortic Aneurysm Formation 
Yoram Aamon, Bijoy K. Khandheria, Irene Meissner, Gary L. Schwartz, JoRean D. Sicks, 
Angels Fought, W. M. O'Fallon, David O. Wiebers, James B. Seward, A. J. Tajik, Mayo 
Clinic and Mayo Foundation, Rochester, Minnesota. 
Backoround: We hypothesized that aortic dilatation is an atherosclerosis-related process. 
Methods: Thoracic aortic dimensions (diameters at the sinuses of Valsalva [SV], ascend- 
ing aorta [AA], aortic arch and descending aorta [DA]) were measured by transesobh- 
ageal echocardiography in 373 subjects (median age 66 yr, range 51-101; 52% men) 
participating in a population-based study (Stroke Prevention: Assessment of Risk in a 
Community), who were free of significant aortic valve disease. The associations between 
aortic atherosclerotic plaques, markers of inflammation (high-sensitivity C-reactive pro- 
tein [hs-CRP] and fibrinogen) and aortic dimensions were examined. Results: Age, male 
gender and body surface area (BSA) were significant determinants of aortic diameters. 
Adjusting for these variables: 1) Thick plaques in the AA (greater or equal to 4 mm) were 
negatively associated with SV diameter (P=-0.03); AA plaques were not associated with 
AA diameter; 2) The presence of aortic arch plaques (of any degree) and thick arch 
plaques (greater or equal to 4 mm) were associated with increased arch diameter (1.41 
mm increase in diameter [.t0.53] in the presence of plaques, P=0.007; 2.18 mm increase 
in diameter ~1.11] in the presence of thick plaques, P=0.05); 3) The presence of DA 
plaques and greater DA plaque thickness were associated with increased DA diameter 
(1.51 mm increase in diameter ~0.53] in the presence of plaques, P=0.004; 0.18 mm 
increase in diameter ~.0.08] per mm increase in plaque thickness, P=-0.03). Adjusting for 
age, gender, BSA and smoking status, hs-CRP and fibrinogen were not significantly 
associated with aortic dimensions (all P values >0.05). Cooclusioo~: Aortic atheroscle- 
rotic plaques are associated with distal, but not proximal, aortic dilatation. These findings 
support the hypothesis that atherosclerotic weakening of the vessel wall plays a role in 
aortic dilatation and, possibly, in aortic aneurysm formation. Systemic inflammatory mark- 
ers are not associated with aortic dimensions, suggesting that non-inflammatory athero- 
sclerotic processes are involved in aortic dilatation, 
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1059-73 Fasting Blood Glucose in the Nondiabetic Range Is a 
Continuous and Graded Risk Factor for CHD 
Byron J, Hoogwerf, Dennis L. Sorecher. Gregory L. Pearce, Joseph P, Frolkis, Monica 
Acevedo, Donald G. Vidt, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Diabetes mellitus (DM) and impaired glucose tolerance are associated 
with several CHD risk factors (RF's) and a >2 fold risk for CHD. Few data exist on 
whether glucose levels in the non-diabetic range are associated with risk for CHD when 
adjusted for multiple risk factors. Objective: We studied the relationships among fasting 
blood glucose (FBG) <126 rag/alL, prevalent CHD, traditional CHD RF's (obesity, dyslipi- 
demia, BP), Framingham risk score and non-traditional CHD RF's (Lp(a), fibrinogen, 
homooysteine (tHcy)) in 2440 consecutive patients without known DM at high risk for 
CHD in a Preventive Cardiology Clinic. Results: There was a trend toward increasing 
values across glucose quintiles for age (P<0.00t), BMt (P<0.001), systolic BP (P<0.001), 
fibrinogen (P<0.001), tHcy (P<0.001). There was a trend for decreasing values for HDL-c 
(P<0.001), as well as for % current smokers (P = 0.02) and Lp(a) (P<0.001). The preva- 
lence of CHD, Framingham risk score and odds ratio (OR) for CHD risk whether unad- 
justed, adjusted for traditional RF's or adjusted for Framingham risk score plus non- 
traditional RF's is significant for the top 3 quintites compare to the lowest (Table). Con° 
cluslons: FBG levels in the non-diabetic range are associated with several traditional 
risk factors for CHD (age, BMI, BP, HDL-c) as well as fibrinogen and tHcy. The OR for 
CHD increases as a continuous function of glucose whether unadjusted or fully adjusted 
for RF's. 
*p<0.001 
Glucose Quintile 1 II III IV V P 
FBG (mg/dL) <_79 80-86 87-92 93-99 100-125 <0.001 
CHD (%) 43 47 53 56 65 <0.001 
Pramingham Risk Score 4.4 5.0 5.3 5.5 6.3 <0.001 
OR (Adjusted all risk factors) 1.0 1.16 1.52* 1.80" 2.78 <0.001 
1059-74 Impact of Fluvaatatin Slow-Release on Low-Density 
Lipoprotein Subfractions in Patients With Type 2 
Diabetes: Baseline Low-Density Lipoprotein Profile 
Determines Specific Mode of Action 
Karl Winkier, Michael M. Hoffmann, Isolde Friedrich, Rita Gl~iser, Claudia Abletshauser, 
Manfred W. Baumstark, Heinrich Wieland, Winfried M~rz, Division of Clinical Chemist~ 
Department of Medicine, Albert Ludwigs Universi~ Freiburg, Germany, Novartis Pharma 
GmbH, NEimberg, German~ 
Background: Patients with type 2 diabetes have an increased coronary artery disease 
risk and lipid metabolism characterized by increased triglycerides, decreased high-den- 
sity Iipoprotein (HDL) cholesterol, and slightly elevated low-density lipoprotein (LDL) cho- 
lesterol. They also have a preponderance of atherogenic dense LDL (dLDL). We 
therefore studied the effect of slow-release (XL) fluvastatin on LDL subfractions in 89 
patients with type 2 diabetes. 
Methods: After a 4-week dietary run-in period, this multicenter, double blind, random- 
ized, parallel-group study compared fluvastatin XL 80 mg (n = 42) with placebo (n = 47), 
given once daily for 8 weeks to patients (mean age: 67 years; range: 39-89 years) with 
mean baseline triglycedde, LDL cholesterol, and HDL cholesterol levels of 211, 154, and 
44.6 mg/dL, respectively. Lipoproteins were isolated by sequential preparative ultracen- 
trifugation and total LDL was separated into 6 subfractions by equilibrium density gradi- 
ent ultraoentrifugation. 
Results: Fluvastatin decreased mean baseline LDL cholesterol (-32%, p<0.001), triglyc- 
erides (-18%, p<O.001), and dLDL (LDL-5: -27%, p<0.001 and LDL-6: -22%, p<0.001), 
these changes being statistically significant compared with placebo. The HDL cholesterol 
increase (3.1%) was not significant, but reached +18% in patients with a baseline HDL 
below 35 mg/dL (n = 10). A baseline dLDL preponderance (apoB in LDL-5 + LDL-6>25 
mg/dL) was present in 3/4 of patients. In these patients, fluvastatin decreased all LDL 
subfractions significantly from baseline (13.7-29.3%), absolute and relative reductions in 
dLDL being greatest. In patients with no baseline dLDL (apoB in LDL-5 + LDL-6<25 mg/ 
dL) only LDL-1 to LDL-3 were significantly reduced, dLDL remaining unchanged. 
Conclusions: Fluvastatin 80 mg XL effectively lowers LDL cholesterol, triglyceddes, and 
dLDL in patients with type 2 diabetes. Fluvastatin also decreases specifically those LDL- 
subfractions that are increased in type 2 diabetes, with or without a predominance of 
dLDL. The antiatherogenic potential of fluvastatin in patients with type 2 diabetes may 
thus be greater than expected from its effects on LDL cholesterol and triglycerides alone. 
1059-75 Ef fect  of Simvastatin on Insulin Resistance and Beta 
Cell Function in Hypercholesterolemic Patients 
Nuri Haksev•r, Fikret Ilgenli, Mustafa Demirci, Go/cuk Naval Hospital Endocrinology, 
Cardiology and Biochemistry Clinics, Kocae/i, Turkey 
Background: The effects of statins on insulin resistance (IR) and I~ celt function ([~cf) are 
not clearly determined. 
Methods: Hypercholesterolemic 113 patients (cholesterol level>200mg/dl, mean age 
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two groups as 62 nondiabetic and 51 diabetic patients, Simvastatin 10 mg/d was given 
for 24 weeks. Fasting glucose (FG), glycohemoglobin (HbAlc) fasting insulin (FI), total 
cholesterol (total-c), high density lipoprotein-cholesterol (HDL-c), triglyceride and low 
density lipoprotein-cholestarol (LDL-c) were measured before and after treatment. IR and 
~cf are assessed with homeostasis model assessment method (HOMA). The formulas 
are as follows; IR = FIx FG / 22.5 and I~cf = 20 x FI/FG-3.5, where FG (mmoblt) and FI 
(mU/I). 
Results: Total-c and LDL-c levels were significantly reduced in both groups. IR non-sig- 
nificantly increased in nondiabetic patients (3.33±2.1 vs 3.40±2.5; p>0.05), and non-sig- 
nificantly improved in diabetics patients (7.43±13.9 vs 5.52±5.3; p>0.05). ~cf increased 
in both groups (180±100 vs 241±165; p<0.005 and 62±69 vs 106±90; p<0.005) respec- 
tively. In order to rule out possible positive effects of antidiabetic therapy, results of 31 
diabetic patients whose oral antidiabetic drug (dAD) doses are increased (group I) com- 
pared with 82 patients who are use only simvastatin or dAD doses were not changed 
(group II). Total -c and LDL -c levels reduced in both groups. IR changed with treatment 
from 3.55 ±3.3 to 3.67±3.4; p<0.0005 in group I and from 9.50±17.1 to 6.20±5.7; 
p<0.0005 in group II, respectively. No correlations were found between change in IR with 
changes in total-c, LDL-c and triglyceride levels. 
Conclusion: Simvastatin treatment has neither negative nor positive effects on IR and 
has positive effect on ~cf in diabetic and non-diabetic hypercholesterolemic patients. 
1059-76 Simvastatin Lowers C-Reactive Protein by 14 Days: An 
Effect Independent of That on LDL Cholesterol 
Julie K. Plsnoe. Kathleen M. Well, Gary Grunwald, Jed Forster, Paul Poirier, Robert H, 
Eckel, The University of Colorado Health Sciences Center, Denver, Colorado. 
Introduction: Highly sensitive C-Reactive Protein (hsCRP) is an independent predictor of 
myocardial infarction. HMG Co-A reductase inhibitors (statins) decrease hsCRP levels 
over time. The early response of hsCRP to statins is unknown. The aims of this study 
were: 1) to determine the rate at which hsCRP levels change after initiation of simvasta- 
tin, and 2) to determine whether changes in hsCRP levels occur independently of change 
in LDL. 
Methods: Cross-over, double-blind study of 40 subjects with elevated LDL. Subjects were 
randomly assigned to one of two groups: (A) simvastatin followed by placebo or (B) pla- 
cebo followed by simvastatin (each for 14 days). HsCRP levels were measured on days 
0, 1, 3, 7, and 14. Levels of acute phase reactants lipoprctein(a) (Lp(a)) and fibrinogen 
were also measured. Fasting LDL was calculated at baseline, day 7 and day 14. 
Results: Baseline levels of hsCRP were not significantly different between groups A and 
B (group A Iog(hsCRP) = 0.83+/-0.15 [mean +/- SEM] versus group B Iog(hsCRP) = 0.72 
+/- 0.15 (p=0.34)). Baseline LDL levels were similar (163 +/- 44 in group A and 166 +/- 38 
in Group B), After initiation of simvastatin mean Iog(hsCRP) fell to 0.71 +/- 0.15 at day 7 
(p=0.57) and to 0.52 +/- 0.15 at day 14 (p=0.0tl). LDL cholesterol fell with simvastatin 
treatment (108 +/- 31at day 7 vs. 98 +/- 31 at day 14). By repeated measures ANOVA, 
there was a significant treatment-time effect of simvastatin on hsCRP over 14 
days(F=2.50, p=0.011 ). This effect was not seen with placebo. There was no correlation 
between treatment-ralatad change in LDL and change in hsCRP. Fibrinogen levels did 
not change significantly, Lp(a) increased slightly (p=0.03). 
Conclusions: While recent studies have shown that statins decrease hsCRP over the 
long term, this is the first study to show that the effect of simvastatin on hsCRP occurs 
early in the treatment course. The effect on LDL cholesterol occurs even earlier (7 days) 
than the fall in hsCRP (14 days), but the change in hsCRP is independent of the change 
in LDL cholesterol. In addition, this early effect on hsCRP appears to occur indepen- 
dently of changes in other acute phase reactants. 
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1080-82 Activity of Endothelin-1 Is Increased in the Forearm 
Resistance Vessels of Subjects With Hypertension 
Aniu Nohria. Leslie Garratt, Wendy Johnson, Scott Kinlay, Peter Ganz, Mark A. Creager, 
Brigham and Women's Hospital, Boston, Massachusetts. 
Background: Endothelin-1 (ET-t) is a potent vasoconstrictor peptide produced by 
endothelial cells. ET-1 has been postulated to increase vasoconstrictor tone in subjects 
at risk for atherosclerosis, particularly those with hypertension. Vasoconstriction to ET-1 
is mediated principally by the endothelin A (ETA) receptor on vascular smooth muscle 
ceils. Accordingly, we used an ET A specific antagonist, BQ-123 to test the hypothesis 
that ET-1 increases vascular resistance selectively in subjects with hypertension com- 
pared to people with other risk factors. 
Methods: BQ-123 was infused at 100 nmol/min for 80 minutes into the brachial artery of 
10 subjects whose only risk factor was hypertension (mean arterial pressure = 106-+ 15; 
mean+SD), 12 subjects with only dyslipidemia (total cholesterol = 273-+22 mg/dl), 10 
active smokers (32-+15 pack years), and 11 healthy, age-matched controls. None of the 
subjects had clinica~ evidence of atherosclerosis. Forearm blood flow (FBF) was mea- 
sured by venous occlusion plethysmogrephy. 
Results: BQ-123 induced significant vasodilatation in the hypertensive subjects com- 
pared to controls. FBF increased by 38% from 2.1:~0.7 to 2.9!-_1.2 ml/dl/min (p<0.05). 
FBF did not change in response to BQ-123 in subjects with dyslipidemia, smokers or 
healthy controls. Similarly, BQ-123 reduced forearm vascular resistance only in hyper- 
tensive subjects (from 55.9+19.8 to 40.4+13.9 mm Hg per ml/dl/min). 
Conclusion: ET-1, acting via the ET A receptor, increases the tone of resistance vessels 
in subjects with hypertension, but not In subjects with dyslipidemia or smokers. These 
results indicate that endothelin contributes to the pathophysiology of hypertension. 
Endothelin antagonists may be beneficial for the treatment of hypertension, but not for 
vascular dysfunction associated with other risk factors for atherosclerosis. 
1080-83 Heine Oxygenase Antagonism Inhibits Endothelium- 
Dependent Vseodllation in the Normal Human Forearm 
Circulation 
Julian P. Halcox. Rita Mincemoyer, Gloria Zatos, Arshed A. Quyyumi, NHLBI, Bethesda, 
Maryland. 
Background: Carbon monoxide (CO) mediates smooth muscle relaxation via generation 
of cyclic GMP in a manner analagous to nitric oxide. CO is generated from heme in 
endothelial cells by the constitutive enzymatic action of hems oxygenase. We hypothe- 
sized that endogenous CO contributes to endothelium-dependent vasomotor function in 
the human forearm circulation. 
Methods: In 5 healthy volunteers, we studied the effect of the heme oxygenase inhibitor 
tin mesoporphyrin (SNMP, 112.5nmol/min) on endothelium-dependent forearm vasodila- 
tion by acetylcholine (7.5 - 30 p.g/min). In a further 10 healthy subjects, the effect of 
SNMP on the response to ecetylcholine was also determined during inhibition of nitric 
oxide synthase and cyclooxygenase by L-NMMA (4~mol/min) and aspinn (lg by mouth), 
respectively. Sodium nitroprusside (1.6-6.4 ~g/min) was also administered before and 
after SNMP to test endothelium-independent function. Drugs were infused into the bra- 
chial artery and forearm blood flow (FBF) and vascular resistance (FVR) were measured 
by plethysmography. 
Results: SNMP did not affect basal forearm vasomotor tone or the dose response curve 
to acetylcholine. When the study was performed during co-administration of L-NMMA 
and aspirin, basal FBF and FVR were also unchanged after SNMP. However, the FBF 
and FVR dose response curves with acetylcholine (ANOVA p=0.025 and p=0.026, 
respectively), but not with sodium nitroprusside (ANOVA p=0.22 and p=0.29 respec- 
tively) were attenuated after SNMP; thus FVR was 21% greater at the peak dose of ace- 
tylcholine after SNMP. 
Conclusions: Our findings suggest that inhibition of hems oxygenase attenuates endct- 
helium-dependent but not -independent vasodilation in the normal human forearm 
microvasculature after inhibition of nitric oxide and prostanglandin synthesis. Thus, CO 
may contribute to endothelium-dependent vasodilation in conditions characterized by 
reduced nitric oxide bioavailability. 
1080-84 Endothelial Dysfunction Accelerates Hypertensive 
Evolution 
Tatsuaki Murakami. Yoshiyuki Arei, Fukui Cardiovascular Center, Fukui, Japan. 
Background: Although hypertension has great impact to develop cardiovascular dis- 
eases, evolutional mechanism of hypertension remains partially clarified. On the other 
hand, endothelial dysfunction (ED) is thought o affect atherogenic processes, there has 
been little clinical evidence for the relationship between clinical manifestation of cardio- 
vascular disease and ED. This study investigated whether noninvasively evaluated ED 
has clinical influences on hypertensive evolution (HTE). Methods: Vasomotor dysfunc- 
tion was graded by noninvasively measured reactive changes in lumen diameter of right 
brachial artery following transient occlusion for 5 minutes (FMD; flow-mediated endothe- 
lium-dependent vasodilation), and after sublingual administration of (300p.g) glyceril tdni- 
trate (TNG; endothelium-indepeodent vasodilation) using high resolution 
ultrasonography in consecutive 365 ambulatory patients who underwent he above vaso- 
motor function tests. The enrolled patients were categorized into three groups according 
to the values of FMD and TNG, and their blood pressure was followed-up for no less than 
36 months. We prospectively followed-up HTE defined as more than two stage upgrade 
of hypertension defined by world health organization or new administration of an antihy- 
pertensive agent. Results: For a mean follow-up period of 54 months (range; 36 to 73) 
with 100% follow-up, the patients with severe endothelial dysfunction (FMD<4%; Group- 
L, n=121), more frequently manifested HTE [Group-L versus Group-M with mild endothe- 
lial dysfunction (4%_<FMD<8%, n=121) plus Group-H with preserved endothelial function 
(FMD 8% or more, n=123): 28 (23.1%) versus 12 (9.9%) plus 5(4.2%), p<0.001, by 
Kaplan-Meier analysis]. There was no significant association between TNG and HTE. 
Cox proportional hazard model analysis showed that severe endothelial dysfunction 
(odds ratio=3.29, 95%confidential interval; 1.57-7.28, p<0.0t) was independently associ- 
ated with future HTE. Conclusion: These results suggest noninvasive ultrasonic evalu- 
ated endothelial dysfunction is a great practical predictor for future hypertensive 
evolution. 
1080-85 Phys ica l  Ac t iv i ty  in Pat ients  With Coronary  Ar tery  
Disease: Effects on Endothelial Function and NAD(P)H 
Oxidase-Expression 
Rainer Hambrecht, Sandra Erbs, Volker Adams, Yves Baither, Nicolle Kr~inkel, Yanwen 
Shu, Silke Krabbes, Jan F. Gummert, Friedrich W. Mohr, Gerhard Schuier, University of 
Leipzig - Heart Center, Leipzig, Germany. 
For patients (pts) with coronary artery disease (CAD), coronary endothelial function, and 
particularly nitric oxide-mediated vasodilation are clearly enhanced by physical exercise 
training (ET), The molecular basis for this improvement is still unclear. To address this 
issue we examined the effect of ET on endothelial function of the left internal mammadal 
artery (LIMA) in vivo and in vitro and determined whether ET affects the expression level 
of the subunit gp91phox of the NAD(P)H oxidase, which is known to play an important 
roJe in 02-, formation. 
Thirty-two symptomatic pts with CAD, who were scheduled for elective coronary artery 
